Kantify

24/12/2025

10/07/2025

For those who find us a tiny bit too silent on Facebook, follow the link and join us on LinkedIn !
https://tinyurl.com/KantifyLN

03/04/2025

No! This photo is not AI edited: a heart-shaped sun ray appeared right during our last team photo!❤️
Meet below a team of people working every day with a lot of ❤️, talent, and AI - to accelerate the discovery of therapies for patients who need them the most.

02/01/2025

A new year is starting: hello, 2025! ⭐

2024 has been quite a special year at Kantify. We have:...made significant breakthroughs and discoveries in cancer and rare diseases...discovered unknown mechanisms of misunderstood diseases...taken giant steps in an accelerated timeline to find promising medicines...discovered the unknown life of medicines in the body

So, what will we achieve in 2025? Well, we can't wait to tell you more 😉

In the meantime, we wish you the VERY BEST for this year to come.

12/12/2024

Kantify is excited to report its joint progress with The Johns Hopkins University School of Medicine and Dr Ranjan Perera's lab on the discovery of drugs for prostate cancer.
While a traditional small molecule discovery screening requires testing 20,000 to 100,000 molecules to find 1 hit, we have tested only 5 molecules to validate... 4.

We are extremely proud of these results and are looking forward to helping patients!

Congrats to Ranjan Perera, Menglang Yuan, Maxime Georges, Nicolas Maignan, Nik Subramanian, David Papazian

⏩ Full article can be found as a first comment below this post.
https://kantify.com/insights/AI_prostate_cancer_Kantify_JohnsHopkins

26/11/2024

[DIAZEPAM - VA**UM] [PREGNANCY]
Today, we're unveiling the latest small molecule drug screened by our AI platform, Sapian.
Many of you are familiar with this medication—it was the 169th most prescribed drug in the United States in 2022, with over 3 million prescriptions.
This widely used drug is Diazepam, also known as Va**um.

In our newly published white paper, "AI for Safer Medications: A Deep Dive into Diazepam's (Va**um) Risks," we have leveraged Sapian to predict unknown biological off-targets of Diazepam and uncover how they link to its known side effects.

🔍 Why is this important?
- Enhanced Drug Safety: Understanding these off-targets can lead to safer prescribing practices and inform risk assessments.
- Innovative Drug Discovery: Demonstrates the power of AI in uncovering hidden aspects of well-known medications.
- Impactful Insights: Provides fully novel data driven hypotheses for researchers and healthcare professionals in the field.

For those of you active in drug discovery and pharmacology, we highly recommend reading this study. We believe you'll find the results as striking and thought-provoking as we did.

Let's listen to our colleague Jack Dawe, Machine Learning Engineer at Kantify and Lead Author of the White Paper, as he presents this second issue of our "Behind the Pill" series, entitled "AI for Safer Medications: A Deep Dive into Diazepam's (Va**um) Risks."

Access the White Paper here : https://www.kantify.com/insights/ai-for-safer-medications-a-deep-dive-into-diazepams-valium

Nb: if you are a drug hunter with a candidate small molecule to be analyzed by Sapian, please get in touch to understand how you can identify likely side effects even before the molecule leaves your lab.

18/11/2024

⏩⏩Unveiling Soon: The Hidden Mechanisms of a Well-Known Drug

What if a medication you've heard of—or even used—holds secrets that could change the way we understand its effects?

At Kantify, our AI platform Sapian has been hard at work uncovering groundbreaking insights about a drug that's widely prescribed around the world.

On November 25th, we're lifting the veil on this mysterious drug.

Why should you be intrigued?

⏩Cutting-Edge AI Discoveries: We've analyzed over 1.4 billion interactions to reveal unknown connections.
⏩Challenging the Status Quo: This isn't just about one drug; it's about transforming drug discovery and patient safety.
⏩Impact on Global Health: The findings could have useful implications for both medical professionals and patients worldwide.

Set your calendars for November 25th.

30/07/2024

What a thrill to read this article today and to see our (almost complete) team features in such a leading Belgian economics newspaper!
Thanks to L'Echo for relaying our new initiative to reveal the hidden side of drugs thanks to Artificial Intelligence
We are happy to help better understand how drugs work in the body so better treatments can be developed for patients in need of a therapy 🫶

Kantify révolutionne la découverte de médicaments avec l'IA en prédisant leurs effets inconnus.

24/07/2024

[Announcement]
We have known for a while now that it was high time to rename our AI platform for drug discovery.
We unveil this new name today!

"Sapian" is the new name of our Artificial Intelligence platform for drug discovery.

The name "Sapian" is derived from "Sapiens," reflecting the platform's emphasis on intelligence and advanced predictive capabilities. "Sapiens," from the Latin "sapere," means "to be wise" or "to know," and is famously associated with "Homo sapiens," the species name for humans, signifying our unique intellectual abilities.

By naming our AI platform Sapian, we want to underscore how we combine human-like wisdom and advanced artificial intelligence to revolutionize drug discovery and make treatments available for patients, faster.

22/07/2024

On July 22, we celebrate the World Fragile X Day with the FRAXA Research Foundation and many other communities worldwide. Fragile X Syndrome (FXS) is the most common inherited single gene cause of autism.
At Kantify, we're using Artificial Intelligence to develop innovative treatments for Fragile X.

Mathijs van der Lei of UAntwerp (photo) recently presented at the Gordon Research Conferences how we are jointly using a new assay and AI to measure subtle changes in the behavior of FXS mouse models, making drug testing more efficient.
We're testing multiple drugs, targeting different pathways in FXS. We've established an innovative drug screening protocol by combining the multi-electrode array (MEA) for neuronal activity and the live mouse tracker (LMT) for behavior analysis. Preliminary data show alterations in the spontaneous firing and behavior of Fmr1 KO compared to wild-type, offering powerful insights into drug effectiveness.

Stay tuned to find out more about our next discoveries!